Brett Case, PhD

Brett Case, PhD

Instructor in Medicine

In June 2023, Dr. Brett Case joined the Department of Medicine in the Division of Infectious Diseases as an Instructor in Medicine.

Dr. Case’s current research focuses on developing countermeasures against globally emerging or recurring respiratory viral infections such as those caused by coronaviruses, pneumoviruses, and paramyxoviruses. Dr. Case obtained his PhD in the laboratory of Mark R. Denison at Vanderbilt University where he studied the requirements of coronavirus capping and proofreading in immune evasion. Upon joining the Diamond Laboratory in 2018, he initially began studying mechanisms of IFIT-mediated antiviral restriction. However, with the emergence of SARS-CoV-2, he quickly returned to the world of coronaviruses. Since 2020, he has helped lead and support numerous studies including the development of SARS-CoV-2 pathogenesis models, vaccine design and characterization, monoclonal antibody discovery, and protein-based therapeutics. More recently, Dr. Case’s research has expanded to include the development of a pan-Sarbecovirus vaccine, defining the immunological mechanisms of broadly cross-reactive memory B cell responses, and mucosal immunity elicited by infection or vaccination.

  • Bachelor of Science in Biological Sciences, Concentration in Biochemistry, Cellular and Molecular Biology, Chemistry Minor, University of Tennessee, Knoxville, Tennessee (2010)
  • Doctor of Philosophy in Microbiology and Immunology, Vanderbilt University, Nashville, TN (2018)
  • Helen Hay Whitney Foundation Posdoctoral Fellowship (2019-2022)
  • Moderna Global Fellowship (2022-2023)
Selected Publications
  1.  Neutralization, effector function and immune imprinting of Omicron variants. Addetia A*, Piccoli L*, Case JB*, Park YJ*, Beltramello M, Guarino B, Dang H, Pinto D, Scheaffer S, Sprouse K, Bassi J, Silacci-Fregni C, Muoio F, Dini M, Vincenzetti L, Acosta R, Johnson D, Subramanian S, Saliba C, Giurdanella M, Lombardo G, Leoni G, Culap K, McAlister C, Rajesh A, Dellota E, Zhou J, Farhat N, Bohan D, Noack J, Lempp FA, Cameroni E, Whitener B, Giannini O, Ceschi A, Ferrari P, Franzetti-Pellanda A, Biggiogero M, Garzoni C, Zappi S, Bernasconi L, Kim MJ, Schnell G, Czudnochowski N, Franko N, Logue JK, Yoshiyama C, Stewart C, Chu H, Schmid MA, Purcell LA, Snell G, Lanzavecchia A, Diamond M, Corti D, Veesler D. Nature.2023 Sep;621(7979):592-601. doi: 10.1038/s41586-023-06487-6. Epub 2023 Aug 30. PMID: 37648855; PMCID: PMC10511321. * Denotes co-first authorship.
  2.  Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Guarino B, Schmid MA, Rosenthal K, Ren K, Jung A, Droit L, Handley SA, Halfmann PJ, Kawaoka Y, Crowe Jr. JE, Fremont DH, Virgin HW, Loo YM, Esser MT, Purcell LA, Corti D, Diamond MS. Nat Commun. 2022 Jul 2;13(1):3824. doi: 10.1038/s41467-022-31615-7. PMID: 35780162.
  3.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Chen RE*, Winkler ES*, Case JB*, Aziati ID, Bricker TL, Joshi A, Darling TL, Ying B, Errico JM, Shrihari S, VanBlargan LA, Xie X, Gilchuk P, Zost SJ, Droit L, Liu Z, Stumpf S, Wang D, Handley SA, Stine WB Jr, Shi PY, Davis-Gardner ME, Suthar MS, Knight MG, Andino R, Chiu CY, Ellebedy AH, Fremont DH, Whelan SPJ, Crowe JE Jr, Purcell L, Corti D, Boon ACM, Diamond MS. Nature. 2021 Jun 21. doi: 10.1038/s41586-021-03720-y. PMID: 341539.  * Denotes co-first authorship

View publications on